RTP Mobile Logo
What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer (Webinar Audio Proceedings)
Released July 2024

Featuring perspectives from Dr Kevin Kalinsky and Dr Heather McArthur. Published July 10, 2024. (Webinar Audio Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, breast surgeons, hematology-oncology fellows, radiation oncologists and other healthcare professionals involved in the treatment of breast cancer.

    LEARNING OBJECTIVES

    • Consider available research data evaluating anti-PD-1/PD-L1 antibody-based approaches for patients with localized triple-negative breast cancer (TNBC), and consider the role of these strategies in clinical practice.
    • Review available clinical trial data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for newly diagnosed PD-L1-positive metastatic TNBC (mTNBC), and use this information to identify patients who may be appropriate for this approach.
    • Evaluate published research findings, clinical factors (eg, age, performance status, prior therapeutic exposure, level of HER2 expression) and individual preferences in the selection and sequencing of available therapeutic agents for patients with PD-L1-negative mTNBC or for those who experience disease progression on front-line chemoimmunotherapy.
    • Appreciate available clinical trial data with approved antibody-drug conjugates for patients with mTNBC to determine how to optimally incorporate these agents into current treatment algorithms.
    • Appraise published efficacy and safety data with PARP inhibitors for patients with localized or metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
    • Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for TNBC.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
    Successful completion of these CME activities, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

    Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology. 

    PRIVACY POLICY
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/WCWtK2024/TNBC/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/WCWtK2024/TNBC/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/WCWtK2024/TNBC/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/WCWtK2024/TNBC.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Kevin Kalinsky, MD, MS
    Professor
    Department of Hematology and Medical Oncology
    Emory University School of Medicine
    Director, Glenn Family Breast Center
    Director, Division of Medical Oncology
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Menarini Silicon Biosystems, Merck, Mersana Therapeutics Inc, Myovant Sciences, Puma Biotechnology Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreement: Merck; Contracted Research: Ambrx, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Novartis; Nonrelevant Financial Relationship: ADC Therapeutics (spouse).

    Heather McArthur, MD, MPH
    Associate Professor, Department of Internal Medicine
    Clinical Director, Breast Cancer Program
    Komen Distinguished Chair in Clinical Breast Cancer Research
    UT Southwestern Medical Center
    Dallas, Texas

    Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Moderna, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, BTG Pharmaceuticals, Merck (to institution).

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, ServierPharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Merck.

    Release date: July 2024
    Expiration date: July 2025

    After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):